In a letter addressed to FDA Commissioner Robert Califf, Republican leaders of the House Committee on Energy and Commerce and two of its subcommittees raised questions about the increasing number of clinical trials conducted in China by companies seeking FDA approval for “me-too” checkpoint inhibitor drugs.
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure.
